Handa Pharmaceuticals, Inc. (TPEX:6620)
75.00
-2.40 (-3.10%)
Feb 11, 2026, 1:30 PM CST
Handa Pharmaceuticals Revenue
Handa Pharmaceuticals had revenue of 489.53M TWD in the quarter ending September 30, 2025, with 127.13% growth. This brings the company's revenue in the last twelve months to 1.62B, up 71.59% year-over-year. In the year 2024, Handa Pharmaceuticals had annual revenue of 830.67M, down -24.92%.
Revenue (ttm)
1.62B
Revenue Growth
+71.59%
P/S Ratio
7.30
Revenue / Employee
n/a
Employees
13
Market Cap
11.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 830.67M | -275.65M | -24.92% |
| Dec 31, 2023 | 1.11B | 908.64M | 459.66% |
| Dec 31, 2022 | 197.68M | 168.44M | 576.16% |
| Dec 31, 2021 | 29.24M | 376.00K | 1.30% |
| Dec 31, 2020 | 28.86M | -55.21M | -65.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.40B |
| YungShin Global Holding | 8.37B |
| Standard Chemical & Pharmaceutical | 6.91B |
| TTY Biopharm Company | 6.50B |
| Synmosa Biopharma | 6.11B |
| Formosa Laboratories | 4.90B |
| ScinoPharm Taiwan | 3.19B |
| SCI Pharmtech | 1.39B |